Gene Silencing Biotech ADARx Makes Some Noise With $535M Stock Market Debut
Posted
Frank Vinluan (via MedCity News)
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration.
The post Gene Silencing Biotech ADARx Makes Some Noise With $535M Stock Market Debut appeared first on MedCity News.
